

पेटेंट कार्यालय  
शासकीय जर्नल

**OFFICIAL JOURNAL  
OF  
THE PATENT OFFICE**

---

---

निर्गमन सं. 43/2025  
ISSUE NO. 43/2025

शुक्रवार  
FRIDAY

दिनांक: 24/10/2025  
DATE: 24/10/2025

---

---

पेटेंट कार्यालय का एक प्रकाशन  
PUBLICATION OF THE PATENT OFFICE

(12) PATENT APPLICATION PUBLICATION

(21) Application No.202511090020 A

(19) INDIA

(22) Date of filing of Application :21/09/2025

(43) Publication Date : 24/10/2025

(54) Title of the invention : DESIGN AND DEVELOPMENT OF HYBRID COUMARIN-QUINAZOLINE ANALOGUES AS MULTIFUNCTIONAL AGENTS TARGETING OXIDATIVE STRESS, INFLAMMATORY PATHWAYS, AND TUMOR CELL PROLIFERATION

(51) International classification	:A61P0035000000, A61P0029000000, A61P0039060000, A61K0038000000, A61P0017060000	(71)Name of Applicant : <b>1)Aniket Kakkar</b> Address of Applicant :Assistant Professor, Department of Pharmacy, Sahu Onkar Saran School of Pharmacy, Faculty of Pharmacy, IFTM University, Moradabad, Uttar Pradesh, India Uttar Pradesh India <b>2)Tanmay Ghosh</b> <b>3)Sanmati Kumar Jain</b> <b>4)Paresh Kapoor Yadav</b> <b>5)Nilanjan Pahari</b> <b>6)Varaganti Sai Chitra Prathyusha</b> <b>7)Gopi Reddy Alugubelli</b> <b>8)Sumit Kumar</b> <b>9)Jannat ul Firdaus</b> <b>10)Satyam Additya</b> <b>11)Krishn Kumar Barmase</b> <b>12)Prabhat Kumar</b>
(31) Priority Document No	:NA	(72)Name of Inventor : <b>1)Aniket Kakkar</b> <b>2)Tanmay Ghosh</b> <b>3)Sanmati Kumar Jain</b> <b>4)Paresh Kapoor Yadav</b> <b>5)Nilanjan Pahari</b> <b>6)Varaganti Sai Chitra Prathyusha</b> <b>7)Gopi Reddy Alugubelli</b> <b>8)Sumit Kumar</b> <b>9)Jannat ul Firdaus</b> <b>10)Satyam Additya</b> <b>11)Krishn Kumar Barmase</b> <b>12)Prabhat Kumar</b>
(32) Priority Date	:NA	
(33) Name of priority country	:NA	
(86) International Application No	:	
Filing Date	:01/01/1900	
(87) International Publication No	: NA	
(61) Patent of Addition to Application Number	:NA	
Filing Date	:NA	
(62) Divisional to Application Number	:NA	
Filing Date	:NA	

(57) Abstract :

[029] The present invention relates to the design, synthesis, and therapeutic application of hybrid coumarin–quinazoline analogues as multifunctional agents targeting oxidative stress, inflammatory pathways, and tumor cell proliferation. These novel compounds combine the antioxidant and anti-inflammatory properties of the coumarin scaffold with the antiproliferative activity of the quinazoline moiety in a single molecular framework. The invention further provides efficient synthetic routes, pharmaceutical compositions, and methods of treatment utilizing the hybrid analogues to manage diseases such as cancer, autoimmune disorders, and oxidative stress–related conditions. By uniting multiple pharmacological activities within one molecule, the invention overcomes the limitations of single-target therapies and offers a promising new class of multitarget therapeutic agents. Accompanied Drawing [FIGS. 1-2]

No. of Pages : 20 No. of Claims : 10